Dengue virus and other flaviviruses including West Nile virus, tick-borne encephalitis virus, and Yellow Fever virus, are widespread, mosquito- or tick-borne human pathogens. About 40% of the world's population lives in areas with substantial risk of dengue transmission, and as many as 100 million people may be infected annually, experiencing dengue fever and potentially lethal severe dengue. Development of a vaccine effective against all four dengue serotypes has been difficult because infection with one ofthe four serotypes does not lead to protective immunity against any of the other three and may lead to enhanced risk of severe, life-threatening illness, especially in children. Antivirals against dengue are of interest due to their potential to reduce the severity of dengue-associated disease as well as to reduce transmission. This proposal will contribute to efforts to develop dengue antivirals by developing mechanistically well-characterized small molecule inhibitors of dengue entry and using these to validate the dengue E protein as an antiviral target in vitro and in vivo. We have previously identified three structurally distinct lead compound series and inhibitors that exhibit a spectrum of activities against dengue virus entry. In the proposed work, we will use a combination of x-ray crystallography, medicinal chemistry, direct protein-small molecule affinity measurements, single-virion fusion and live-cell imaging assays, and resistance studies to optimize the pharmacological activity of our compounds and to elucidate the biochemical and structural mechanisms of action that correspond to potent, pan-serotype inhibition of dengue. Key to these efforts are quantitative assays, analogous to enzymatic activity measurements, for studying the biochemical functions of the viral envelope protein and that allow us to link the biochemical mechanism of small-molecule inhibitors with the step(s) in the cell-entry pathway at which they block infection. Optimized dengue entry inhibitors will be tested in a murine model of dengue infection and pathogenesis. Collectively, our efforts are aimed at producing compounds that can be advanced as preclinical candidates for dengue drug discovery efforts. More broadly, this work establishes the template for a rational approach to the development of small molecule inhibitors of other enveloped viruses as potential antivirals

Public Health Relevance

Although dengue virus is the most widespread mosquito-borne viral disease affecting humans today, there are no antiviral drugs effective against it, nor is there a protective vaccine. Our goal is to identify small, drug like molecules that prevent dengue virus infection by blocking entry into the host cell. These small molecules can then be used to study how the virus enters the host cell and to develop potential antiviral therapeutics.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI109740-03
Application #
9011998
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2016-03-01
Budget End
2017-02-28
Support Year
3
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Harvard Medical School
Department
Type
DUNS #
047006379
City
Boston
State
MA
Country
United States
Zip Code
Coulter, Michael E; Dorobantu, Cristina M; Lodewijk, Gerrald A et al. (2018) The ESCRT-III Protein CHMP1A Mediates Secretion of Sonic Hedgehog on a Distinctive Subtype of Extracellular Vesicles. Cell Rep 24:973-986.e8
Lian, Wenlong; Jang, Jaebong; Potisopon, Supanee et al. (2018) Discovery of Immunologically Inspired Small Molecules That Target the Viral Envelope Protein. ACS Infect Dis 4:1395-1406
de Wispelaere, Melissanne; Lian, Wenlong; Potisopon, Supanee et al. (2018) Inhibition of Flaviviruses by Targeting a Conserved Pocket on the Viral Envelope Protein. Cell Chem Biol 25:1006-1016.e8
Chao, Luke H; Jang, Jaebong; Johnson, Adam et al. (2018) How small-molecule inhibitors of dengue-virus infection interfere with viral membrane fusion. Elife 7:
Pitts, Jared D; Li, Pi-Chun; de Wispelaere, Melissanne et al. (2017) Antiviral activity of N-(4-hydroxyphenyl) retinamide (4-HPR) against Zika virus. Antiviral Res 147:124-130
Salgado, Eric N; Upadhyayula, Srigokul; Harrison, Stephen C (2017) Single-particle detection of transcription following rotavirus entry. J Virol :
Raaben, Matthijs; Jae, Lucas T; Herbert, Andrew S et al. (2017) NRP2 and CD63 Are Host Factors for Lujo Virus Cell Entry. Cell Host Microbe 22:688-696.e5
Wang, May K; Lim, Sun-Young; Lee, Soo Mi et al. (2017) Biochemical Basis for Increased Activity of Ebola Glycoprotein in the 2013-16 Epidemic. Cell Host Microbe 21:367-375
Filippakis, Harilaos; Alesi, Nicola; Ogorek, Barbara et al. (2017) Lysosomal regulation of cholesterol homeostasis in tuberous sclerosis complex is mediated via NPC1 and LDL-R. Oncotarget 8:38099-38112
Clark, Margaret J; Miduturu, Chandra; Schmidt, Aaron G et al. (2016) GNF-2 Inhibits Dengue Virus by Targeting Abl Kinases and the Viral E Protein. Cell Chem Biol 23:443-52

Showing the most recent 10 out of 25 publications